How Recent 340B Changes Impact Specialty Pharmacies In 2025

June 4, 2025340B, Compliance, Covered Entities, Drug Manufacturer Restrictions, News Updates, Readmissions Reduction, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More

Navigating 340B Program Changes in 2025

April 1, 2025340B, 340B ESP, Audit, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Pharmacy

Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More

The Pharmacy Model That Restores Control To 340B Hospitals

January 24, 2025340B, Drug Manufacturer Restrictions, Prescription Discounts, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

How your health system can leverage visibility, your PBM and your pharmacies to achieve your financial and clinical goals.   The systemic problem: Overview The U.S. prescription drug market is a textbook case of waste and inefficiency — one that, in recent years, has disproportionately benefited a handful powerful corporations at the expense of providers, … Read More

So You Want To Build A 340B Specialty Pharmacy. How Hard Can It Be?

December 30, 2024340B, Covered Entities, Drug Manufacturer Restrictions, Specialty Drugs, Specialty Pharmacy

Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialty pharmacy, and did it with no outside support, there’s a good chance you’ll get punched. Yes, it’s that difficult.   POST OUTLINE Why is it so hard to build a 340B specialty … Read More

J&J’s Numbers Reveal The Fallacy Of 340B Price Restrictions

October 25, 2024340B, Covered Entities, Drug Manufacturer Restrictions, PBM, Specialty Drugs, Specialty Pharmacy

POST OUTLINE Introduction: Overview Review of Johnson & Johnson’s drug rebate payments in 2023 J&J’s 2023 profit margin Johnson & Johnson’s real rebate problem 340B and the drug industry as a whole Estimated percentage of drug sales supporting 340B health systems Why the actual number is lower than reported The importance of 340B savings & … Read More

Overcome 340B Restrictions With Software And Human Insight

August 28, 2024340B, 340B ESP, Bedside Prescription Delivery, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Overview, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More

Optimize Your Health System’s Patient Care & ROI With 340B

August 7, 2024340B, 340B ESP, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, Prescription Discounts, Readmissions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of ProxsysRx’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More

Empower Your Health System’s 340B Program With Analytics

July 10, 2024340B, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Medication Compliance, Patient Eligibility, TPA / TPAs

The automated approach to optimizing 340B savings & patient care while overcoming manufacturer restrictions NOTE: The purpose of this article is to highlight features and functionality any 340B platform needs to optimize a health system’s 340B savings and revenue. That said, we determined that the easiest way to report those features was to describe the … Read More

340B Outlook For 2024: Change. Change. And More Change.

April 19, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

POST OUTLINE 1) What we’ve learned. What it means for your 340B program. Overview of ProxsysRx 340B Team experience and successes Dealing with frequent, unexpected changes 2) Potential 340B developments for 2024 National legislation prospects State regulatory changes 3) Legislative & court updates Bill introduced into House Of Representatives Supreme Court overturns 340B restriction cuts … Read More

The Case for Onsite Specialty Pharmacies in 340B Hospitals

April 4, 2024340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More